Clinical Trial Update: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing neoadjuvant eribulin/cyclophosphamide versus docetaxel/cyclophosphamide in locally advanced HER2-negative breast cancer was completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: HER2 Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-08-26